Analytical Data
-
基因名
LILRA1/LIR-6/CD85i
-
简介
LILRA1/LIR-6/CD85i protein serves as a receptor for class I MHC antigens and plays a crucial role in immune recognition and response. Its interaction with class I MHC molecules suggests involvement in monitoring and possibly influencing immune activity. LILRA1/LIR-6/CD85i Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived LILRA1/LIR-6/CD85i protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
- Application
-
别名
CD85i; LILRA1; LIR6; LIR-6; LIR6MGC126563
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O75019-1
-
表达区间
P17-N461
-
蛋白长度
Extracellular Domain
-
分子量
70-80 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LILRB1, also known as CD85j or ILT2 (Immunoglobulin-like transcript 2), is a crucial immune checkpoint receptor belonging to the LILR (Leukocyte Immunoglobulin-like Receptor) family. It is primarily expressed on various immune cells, including monocytes, macrophages, and dendritic cells, where it plays a fundamental role in regulating immune responses. The receptor recognizes major histocompatibility complex (MHC) class I molecules, which allows it to modulate the activation and inhibition of immune cell functions. Due to its immunoregulatory capabilities, LILRB1 is considered a significant player in maintaining immune tolerance and preventing excessive inflammation, making it a potential target for therapeutic interventions in autoimmune diseases and cancer. The development of recombinant LILRB1/CD85j/ILT2 proteins enables researchers to explore its biological functions and interactions in detail, facilitating the understanding of its role in immune modulation. By studying these recombinant proteins, scientists aim to decipher the molecular mechanisms underlying LILRB1 signaling and its impact on immune cell behavior, paving the way for innovative treatments that leverage this checkpoint receptor in immunotherapy and transplant medicine. Overall, LILRB1’s unique properties and its emerging significance in immune regulation underscore the importance of continued research into its potential applications.
